Dr Reddy's to buy nicotine replacement brands from UK-based Haleon for $632 million

The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uspxoX4
via IFTTT